Whole-Brain Atrophy Rate in Idiopathic Parkinson’s Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy
In multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), the absence of surrogate endpoints makes clinical trials long and expensive. We aim to determine annualized whole-brain atrophy rates (a-WBAR) in idiopathic Parkinson’s disease (IPD), MSA, and PSP. Ten healthy controls, 20 IP...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2016/9631041 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850178672283090944 |
|---|---|
| author | C. Guevara K. Bulatova G. J. Barker G. Gonzalez N. Crossley M. J. Kempton |
| author_facet | C. Guevara K. Bulatova G. J. Barker G. Gonzalez N. Crossley M. J. Kempton |
| author_sort | C. Guevara |
| collection | DOAJ |
| description | In multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), the absence of surrogate endpoints makes clinical trials long and expensive. We aim to determine annualized whole-brain atrophy rates (a-WBAR) in idiopathic Parkinson’s disease (IPD), MSA, and PSP. Ten healthy controls, 20 IPD, 12 PSP, and 8 MSA patients were studied using a volumetric MRI technique (SIENA). In controls, the a-WBAR was 0.37%±0.28 (CI 95% 0.17–0.57), while in IPD a-WBAR was 0.54%±0.38 (CI 95% 0.32–0.68). The IPD patients did not differ from the controls. In PSP, the a-WBAR was 1.26%±0.51 (CI 95%: 0.95–1.58). In MSA, a-WBAR was 1.65%±1.12 (CI 95%: 0.71–2.59). MSA did not differ from PSP. The a-WBAR in PSP and MSA were significantly higher than in the IPD group (p=0.004 and p<0.001, resp.). In PSP, the use of a-WBAR required one-half of the patients needed for clinical scales to detect a 50% reduction in their progression. In MSA, one-quarter of the patients would be needed to detect the same effect. a-WBAR is a reasonable candidate to consider as a surrogate endpoint in short clinical trials using smaller sample sizes. The confidence intervals for a-WBAR may add a potential retrospective application for a-WBAR to improve the diagnostic accuracy of MSA and PSP versus IPD. |
| format | Article |
| id | doaj-art-c5cbe2e4fdb8412d86204c533b6fe329 |
| institution | OA Journals |
| issn | 2090-8083 2042-0080 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-c5cbe2e4fdb8412d86204c533b6fe3292025-08-20T02:18:39ZengWileyParkinson's Disease2090-80832042-00802016-01-01201610.1155/2016/96310419631041Whole-Brain Atrophy Rate in Idiopathic Parkinson’s Disease, Multiple System Atrophy, and Progressive Supranuclear PalsyC. Guevara0K. Bulatova1G. J. Barker2G. Gonzalez3N. Crossley4M. J. Kempton5Facultad de Medicina, Universidad de Chile, Santos Dummont 999, Santiago, ChileFacultad de Medicina, Universidad de Chile, Santos Dummont 999, Santiago, ChileDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London SE5 8AF, UKFacultad de Medicina, Universidad de Chile, Santos Dummont 999, Santiago, ChileDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London SE5 8AF, UKDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London SE5 8AF, UKIn multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), the absence of surrogate endpoints makes clinical trials long and expensive. We aim to determine annualized whole-brain atrophy rates (a-WBAR) in idiopathic Parkinson’s disease (IPD), MSA, and PSP. Ten healthy controls, 20 IPD, 12 PSP, and 8 MSA patients were studied using a volumetric MRI technique (SIENA). In controls, the a-WBAR was 0.37%±0.28 (CI 95% 0.17–0.57), while in IPD a-WBAR was 0.54%±0.38 (CI 95% 0.32–0.68). The IPD patients did not differ from the controls. In PSP, the a-WBAR was 1.26%±0.51 (CI 95%: 0.95–1.58). In MSA, a-WBAR was 1.65%±1.12 (CI 95%: 0.71–2.59). MSA did not differ from PSP. The a-WBAR in PSP and MSA were significantly higher than in the IPD group (p=0.004 and p<0.001, resp.). In PSP, the use of a-WBAR required one-half of the patients needed for clinical scales to detect a 50% reduction in their progression. In MSA, one-quarter of the patients would be needed to detect the same effect. a-WBAR is a reasonable candidate to consider as a surrogate endpoint in short clinical trials using smaller sample sizes. The confidence intervals for a-WBAR may add a potential retrospective application for a-WBAR to improve the diagnostic accuracy of MSA and PSP versus IPD.http://dx.doi.org/10.1155/2016/9631041 |
| spellingShingle | C. Guevara K. Bulatova G. J. Barker G. Gonzalez N. Crossley M. J. Kempton Whole-Brain Atrophy Rate in Idiopathic Parkinson’s Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy Parkinson's Disease |
| title | Whole-Brain Atrophy Rate in Idiopathic Parkinson’s Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy |
| title_full | Whole-Brain Atrophy Rate in Idiopathic Parkinson’s Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy |
| title_fullStr | Whole-Brain Atrophy Rate in Idiopathic Parkinson’s Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy |
| title_full_unstemmed | Whole-Brain Atrophy Rate in Idiopathic Parkinson’s Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy |
| title_short | Whole-Brain Atrophy Rate in Idiopathic Parkinson’s Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy |
| title_sort | whole brain atrophy rate in idiopathic parkinson s disease multiple system atrophy and progressive supranuclear palsy |
| url | http://dx.doi.org/10.1155/2016/9631041 |
| work_keys_str_mv | AT cguevara wholebrainatrophyrateinidiopathicparkinsonsdiseasemultiplesystematrophyandprogressivesupranuclearpalsy AT kbulatova wholebrainatrophyrateinidiopathicparkinsonsdiseasemultiplesystematrophyandprogressivesupranuclearpalsy AT gjbarker wholebrainatrophyrateinidiopathicparkinsonsdiseasemultiplesystematrophyandprogressivesupranuclearpalsy AT ggonzalez wholebrainatrophyrateinidiopathicparkinsonsdiseasemultiplesystematrophyandprogressivesupranuclearpalsy AT ncrossley wholebrainatrophyrateinidiopathicparkinsonsdiseasemultiplesystematrophyandprogressivesupranuclearpalsy AT mjkempton wholebrainatrophyrateinidiopathicparkinsonsdiseasemultiplesystematrophyandprogressivesupranuclearpalsy |